Skip to content

Enhancing the Predictive Value of Periportal Effusion on MSCT for Clinical Prognosis in Patients with Severe Hepatitis

Enhancing the Predictive Value of Periportal Effusion on MSCT for Clinical Prognosis in Patients with Severe Hepatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117986
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe hepatitis

Interventions

The portal vein effusion group:None
The non-portal vein effusion group:None

Sponsors

The Ninth Hospital of Nanchang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The discharge diagnosis of inpatients at this hospital meets the criteria for severe hepatitis; 2. Comprehensive contrast-enhanced MSCT imaging data and clinical liver biochemical indicators are available; 3. Age range: 18–80 years.

Exclusion criteria

Exclusion criteria: 1. History of liver surgery or interventional therapy; 2. Liver tumours; 3. Intrahepatic, extrahepatic, and other systemic pathologies (biliary tract disease, pancreatitis, portal vein thrombosis, cardiac insufficiency, renal insufficiency, hypoalbuminaemia, etc.); 4. Traumatic injury; 5. Incomplete imaging or clinical data, or loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Width of the periportal effusion space;Liver function biochemical indicators;

Countries

China

Contacts

Public ContactHuang Zhi Hua

The Ninth Hospital of Nanchang

8278424@qq.com+86 791 8849 9537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026